Biomedical Advanced Research and Development Authority

US Department of Health and Human Services

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile. BARDA’s support includes funding, technical assistance and core services, ranging from a clinical research organization network to Centers for Innovation in Advanced Development and Manufacturing, and a fill-finish manufacturing network. To-date, BARDA has supported 42 FDA approvals for products addressing CBRN, PI, and EID threats. Our mission is accomplished through successful public-private partnerships with industry to share risk, improve efficiency and accelerate development all while sustaining a marketplace that guarantees continued access to countermeasures vital to our national security. Learn More >> Novel Coronavirus DRIVe: Division of Research, Innovation, and Ventures Studies on the Burden, Trajectory, and Forecast for Sepsis CARB-X BARDA TechWatch Meetings BARDA Broad Agency Announcement BARDA Strategic Plan Project BioShield Annual Reports Anthrax Medical Countermeasure Programs BARDA News March 9, 2020: HHS Supports Development of First High-Throughput COVID-19 Diagnostic Test March 6, 2020: HHS Solicits Proposals for Development of Medical Products for Novel Coronavirus February 22, 2020: BARDA Leverages Strong Public-Private Partnerships to Spur a Rapid Response to the Novel Coronavirus Outbreak February 18, 2020: HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus Vaccine February 18, 2020: HHS, Janssen Collaborate To Develop Coronavirus Therapeutics Learn More >> This page last reviewed: February 27, 2020 Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201 U.S. Department of Health and Human Services | USA.gov | GobiernoUSA.gov | HealthCare.gov in Other Languages PHE Logo

Relationships Interlocks Giving Data

Leadership & Staff

Christopher Houchens Acting Director, Division of CBRN Medical Countermeasures, BARDA

• Acting Director, Division of CBRN Medical Countermeasures

Robert Kadlec Assistant Secretary of Health and Human Services for Preparedness and Response

• Position

Rick Bright Former HHS ASPR BARDA head

• Director ('16→Apr '20)

Donations

AstraZeneca PLC

• Grant · 1,200,000,000 USD (Jun '20)

Parents

Office of the Assistant Secretary for Preparedness and Response ASPR leads the nation’s medical and public health preparedness for, response to, and recovery from disasters and public health emergencies.

• Parent Org

U.S. Department of Health and Human Services The United States' Health and Human Services Agency

• Parent Org

Services & Transactions

Phlow Corp generic-drug maker based in Virginia

• contractor · 354,000,000 USD*

Miscellaneous Relationships

AZD1222 Covid-19 Vaccine Developed by AstraZeneca

• Funded By (Jun '20→?)*

Moderna, Inc. Cambridge, MA Based Biotech start-up working with the NIH to develop a COVID-19 vaccine

• Partner

Types	Organization, Government Body
Start date	2006
Website	https://www.phe.gov/about/barda/
Aliases	BARDA, Biomedical Advanced Research and Development Authority (BARDA)